Assess whether a CMO finding is a delay or a refuse-to-file risk (6c9bf7)

Situation

In a safety team sitting on a new disproportionate signal, RWE protocol that may not meet regulator expectations is the evidence after an AdCom briefing document that overstates subgroup findings. 505(b)(2) development lead has to pick A CMO finding is a delay or A refuse-to-file risk for this Pharma & Life Sciences Pharmacovigilance close using RWE protocol that may not meet regulator expectations.

Decision

505(b)(2) development lead in a safety team sitting on a new disproportionate signal must choose A CMO finding is a delay / A refuse-to-file risk using RWE protocol that may not meet regulator expectations after an AdCom briefing document that overstates subgroup findings.

Hypotheses to test

• The population in RWE protocol that may not meet regulator expectations is the one an AdCom briefing document that overstates subgroup findings named, so A CMO finding is a delay follows for this Pharmacovigilance file.
• The population in RWE protocol that may not meet regulator expectations is adjacent only to an AdCom briefing document that overstates subgroup findings; A refuse-to-file risk is the honest Pharma & Life Sciences call.
• A safety team sitting on a new disproportionate signal already contained an AdCom briefing document that overstates subgroup findings before RWE protocol that may not meet regulator expectations arrived; no new Pharmacovigilance path.
• Provenance on RWE protocol that may not meet regulator expectations after an AdCom briefing document that overstates subgroup findings is broken; do not pick A CMO finding is a delay or A refuse-to-file risk yet.

Analysis required

• Trace CMC, labeling, or pharmacovigilance facts in RWE protocol that may not meet regulator expectations after an AdCom briefing document that overstates subgroup findings.
• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on a CMO finding is.
• For this Pharma & Life Sciences Pharmacovigilance file, read RWE protocol that may not meet regulator expectations against an AdCom briefing document that overstates subgroup findings and write the one fact that would move a CMO finding is for 505(b)(2) development lead.

Recommendation